These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 16809735

  • 1. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer.
    Raj GV, Iasonos A, Herr H, Donat SM.
    J Clin Oncol; 2006 Jul 01; 24(19):3095-100. PubMed ID: 16809735
    [Abstract] [Full Text] [Related]

  • 2. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.
    Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G, Bochner BH.
    Cancer; 2006 Aug 01; 107(3):506-13. PubMed ID: 16773629
    [Abstract] [Full Text] [Related]

  • 3. Impact of the CKD-EPI equation for estimating renal function on eligibility for cisplatin-based chemotherapy in patients with urothelial cancer.
    Tsao CK, Moshier E, Seng SM, Godbold J, Grossman S, Winston J, Oh WK, Galsky MD.
    Clin Genitourin Cancer; 2012 Mar 01; 10(1):15-20. PubMed ID: 22130294
    [Abstract] [Full Text] [Related]

  • 4. The potential nephrotoxic effects of intensity modulated radiotherapy delivered to the para-aortic area of women with gynecologic malignancies: preliminary results.
    Varlotto JM, Gerszten K, Heron DE, Comerci J, Gautam S, Selvaraj R, Lalonde R, Chura JC.
    Am J Clin Oncol; 2006 Jun 01; 29(3):281-9. PubMed ID: 16755182
    [Abstract] [Full Text] [Related]

  • 5. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
    Muramaki M, Miyake H, Kurahashi T, Takenaka A, Inoue TA, Fujisawa M.
    Int J Urol; 2008 Apr 01; 15(4):314-8. PubMed ID: 18380818
    [Abstract] [Full Text] [Related]

  • 6. Cisplatin-based chemotherapy in renal transplant recipients. A case report and a review of the literature.
    Benisovich VI, Silverman L, Slifkin R, Stone N, Cohen E.
    Cancer; 1996 Jan 01; 77(1):160-3. PubMed ID: 8630924
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Occult renal impairment is common in patients with peripheral vascular disease and normal serum creatinine.
    Rashid ST, Salman M, Agarwal S, Hamilton G.
    Eur J Vasc Endovasc Surg; 2006 Sep 01; 32(3):294-9. PubMed ID: 16716614
    [Abstract] [Full Text] [Related]

  • 15. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
    Soga N, Arima K, Sugimura Y.
    Int J Urol; 2008 Sep 01; 15(9):800-3. PubMed ID: 18651862
    [Abstract] [Full Text] [Related]

  • 16. Chemotherapy of urothelial tract cancer: Memorial Sloan-Kettering Cancer Center experience.
    Yagoda A.
    Important Adv Oncol; 1988 Sep 01; ():143-59. PubMed ID: 3042602
    [No Abstract] [Full Text] [Related]

  • 17. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction.
    Smilde TD, van Veldhuisen DJ, Navis G, Voors AA, Hillege HL.
    Circulation; 2006 Oct 10; 114(15):1572-80. PubMed ID: 17015793
    [Abstract] [Full Text] [Related]

  • 18. Preoperative hydronephrosis: independent predictor for changes in renal function following nephroureterectomy.
    Hoshino K, Kikuchi E, Tanaka N, Akita H, Ito Y, Miyajima A, Jinzaki M, Oya M.
    Jpn J Clin Oncol; 2012 Mar 10; 42(3):202-7. PubMed ID: 22246718
    [Abstract] [Full Text] [Related]

  • 19. Long-term survival after combined modality treatment in metastatic bladder cancer patients presenting with supra-regional tumor positive lymph nodes only.
    de Vries RR, Nieuwenhuijzen JA, Meinhardt W, Bais EM, Horenblas S.
    Eur J Surg Oncol; 2009 Apr 10; 35(4):352-5. PubMed ID: 18722076
    [Abstract] [Full Text] [Related]

  • 20. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.
    Galsky MD, Moshier E, Krege S, Lin CC, Hahn N, Ecke T, Sonpavde G, Godbold J, Oh WK, Bamias A.
    Cancer; 2013 Aug 15; 119(16):3012-9. PubMed ID: 23720216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.